Martin G. Klatt

867 total citations
20 papers, 494 citations indexed

About

Martin G. Klatt is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Martin G. Klatt has authored 20 papers receiving a total of 494 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 16 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Martin G. Klatt's work include Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (11 papers) and vaccines and immunoinformatics approaches (8 papers). Martin G. Klatt is often cited by papers focused on Immunotherapy and Immune Responses (13 papers), CAR-T cell therapy research (11 papers) and vaccines and immunoinformatics approaches (8 papers). Martin G. Klatt collaborates with scholars based in United States, Germany and Slovakia. Martin G. Klatt's co-authors include Aviv Regev, E. John Wherry, R. Anthony Barnitz, Madeleine E. Lemieux, Makoto Kurachi, W. Nicholas Haining, Michael DiIorio, Kathleen B. Yates, Pamela M. Odorizzi and Jernej Godec and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Nature Immunology.

In The Last Decade

Martin G. Klatt

20 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin G. Klatt United States 12 350 271 167 52 43 20 494
Gregor Manukian United States 7 396 1.1× 324 1.2× 155 0.9× 43 0.8× 39 0.9× 13 545
Dries Renmans Belgium 8 296 0.8× 244 0.9× 253 1.5× 70 1.3× 60 1.4× 9 500
Casey Moore United States 9 315 0.9× 253 0.9× 191 1.1× 73 1.4× 31 0.7× 16 536
Annika De Sousa Linhares Austria 7 212 0.6× 270 1.0× 95 0.6× 49 0.9× 23 0.5× 11 400
Thérèse Liechtenstein Spain 12 347 1.0× 252 0.9× 168 1.0× 19 0.4× 59 1.4× 15 505
Korina G. Veenstra United States 6 317 0.9× 216 0.8× 139 0.8× 38 0.7× 54 1.3× 8 484
Y. Maurice Morillon United States 11 386 1.1× 294 1.1× 85 0.5× 47 0.9× 77 1.8× 19 527
Maria Liljefors Sweden 12 243 0.7× 224 0.8× 133 0.8× 85 1.6× 30 0.7× 20 451
Kevin M. Friedman United States 8 283 0.8× 405 1.5× 193 1.2× 29 0.6× 55 1.3× 15 530
Amber N. Woods United States 8 497 1.4× 374 1.4× 113 0.7× 31 0.6× 19 0.4× 12 655

Countries citing papers authored by Martin G. Klatt

Since Specialization
Citations

This map shows the geographic impact of Martin G. Klatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin G. Klatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin G. Klatt more than expected).

Fields of papers citing papers by Martin G. Klatt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin G. Klatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin G. Klatt. The network helps show where Martin G. Klatt may publish in the future.

Co-authorship network of co-authors of Martin G. Klatt

This figure shows the co-authorship network connecting the top 25 collaborators of Martin G. Klatt. A scholar is included among the top collaborators of Martin G. Klatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin G. Klatt. Martin G. Klatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klatt, Martin G., et al.. (2023). The landscape of MHC-presented phosphopeptides yields actionable shared tumor antigens for cancer immunotherapy across multiple HLA alleles. Journal for ImmunoTherapy of Cancer. 11(9). e006889–e006889. 4 indexed citations
2.
Banks, Lauren B., Smita S. Chandran, Emily K. Slotkin, et al.. (2023). 343 Defining and therapeutically targeting a fusion-derived public neoantigen in desmoplastic small round cell tumor using T-cell receptor gene therapy. SHILAP Revista de lepidopterología. A392–A392. 1 indexed citations
3.
Hasan, Aisha, Ekaterina Doubrovina, Rosa Sottile, et al.. (2022). Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T cells in adoptive therapy. Blood Advances. 6(16). 4859–4872. 13 indexed citations
4.
Dao, Tao, Tatyana Korontsvit, Thomas E. White, et al.. (2022). A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex. PLoS ONE. 17(3). e0265534–e0265534. 11 indexed citations
5.
Dao, Tao, Tatyana Korontsvit, Martin G. Klatt, et al.. (2022). A TCR mimic monoclonal antibody reactive with the “public” phospho-neoantigen pIRS2/HLA-A*02:01 complex. JCI Insight. 7(5). 15 indexed citations
6.
Bourne, Christopher M., Tao Dao, Ron S. Gejman, et al.. (2022). Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment. Blood Advances. 6(14). 4107–4121. 6 indexed citations
7.
Klatt, Martin G., Tao Dao, Zhiyuan Yang, et al.. (2022). A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. Blood. 140(8). 861–874. 15 indexed citations
8.
Bourne, Christopher M., et al.. (2021). Low-dose CDK4/6 inhibitors induce presentation of pathway specific MHC ligands as potential targets for cancer immunotherapy. OncoImmunology. 10(1). 1916243–1916243. 18 indexed citations
9.
Klatt, Martin G., et al.. (2021). Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. Frontiers in Immunology. 11. 585385–585385. 18 indexed citations
10.
Klatt, Martin G., et al.. (2020). Solving an MHC allele–specific bias in the reported immunopeptidome. JCI Insight. 5(19). 15 indexed citations
11.
Gejman, Ron S., Martin G. Klatt, Aaron Y. Chang, et al.. (2020). Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunology Research. 8(5). 672–684. 26 indexed citations
12.
Klatt, Martin G., et al.. (2020). An input-controlled model system for identification of MHC bound peptides enabling laboratory comparisons of immunopeptidome experiments. Journal of Proteomics. 228. 103921–103921. 2 indexed citations
13.
Dao, Tao, Martin G. Klatt, Tatyana Korontsvit, et al.. (2020). Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. Cancer Immunology Immunotherapy. 70(5). 1189–1202. 8 indexed citations
14.
Klatt, Martin G., Zhiyuan Yang, Jianying Liu, et al.. (2020). A TCR Mimic Antibody-Directed CAR T Cell Specific for Intracellular NDC80 Is Broadly Cancer Reactive and Displays High Activity Against Hematological Malignancies. Blood. 136(Supplement 1). 20–21. 1 indexed citations
15.
Oh, Claire Y., Martin G. Klatt, Christopher M. Bourne, et al.. (2019). ALK and RET Inhibitors Promote HLA Class I Antigen Presentation and Unmask New Antigens within the Tumor Immunopeptidome. Cancer Immunology Research. 7(12). 1984–1997. 31 indexed citations
16.
Chandran, Smita S., Jiaqi Ma, Martin G. Klatt, et al.. (2019). Abstract CN01-03: T cell receptor gene therapy for a public neoantigen derived from mutated PIK3CA, a dominant driver oncogene in breast and endometrial cancers. Molecular Cancer Therapeutics. 18(12_Supplement). CN01–3. 4 indexed citations
17.
Dao, Tao, Andrew Scott, Casey A. Jarvis, et al.. (2019). Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody. OncoImmunology. 8(7). e1570778–e1570778. 21 indexed citations
18.
Klatt, Martin G., et al.. (2018). Epigenetic Drug Treatment Induces Presentation of New Class of Non-Exonic, Cryptic Neoantigens in Acute Myeloid Leukemia Cells. Blood. 132(Supplement 1). 2717–2717. 3 indexed citations
19.
Klatt, Martin G., Daniel J. Kowalewski, Heiko Schuster, et al.. (2016). Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design. OncoImmunology. 5(8). e1204504–e1204504. 15 indexed citations
20.
Kurachi, Makoto, R. Anthony Barnitz, Nir Yosef, et al.. (2014). The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8+ T cells. Nature Immunology. 15(4). 373–383. 267 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregor Manukian Breakdown of academic impact, for papers by Dries Renmans Breakdown of academic impact, for papers by Casey Moore Breakdown of academic impact, for papers by Annika De Sousa Linhares Breakdown of academic impact, for papers by Thérèse Liechtenstein Breakdown of academic impact, for papers by Korina G. Veenstra Breakdown of academic impact, for papers by Y. Maurice Morillon Breakdown of academic impact, for papers by Maria Liljefors Breakdown of academic impact, for papers by Kevin M. Friedman Breakdown of academic impact, for papers by Amber N. Woods
Rankless by CCL
2026